CN1649845A - 蝇蕈碱拮抗剂 - Google Patents

蝇蕈碱拮抗剂 Download PDF

Info

Publication number
CN1649845A
CN1649845A CNA038094436A CN03809443A CN1649845A CN 1649845 A CN1649845 A CN 1649845A CN A038094436 A CNA038094436 A CN A038094436A CN 03809443 A CN03809443 A CN 03809443A CN 1649845 A CN1649845 A CN 1649845A
Authority
CN
China
Prior art keywords
compound
alkyl
group
formula
neurodegenerative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038094436A
Other languages
English (en)
Chinese (zh)
Inventor
C·D·博伊尔
W·J·格林李
S·查卡拉曼尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1649845A publication Critical patent/CN1649845A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNA038094436A 2002-04-26 2003-04-24 蝇蕈碱拮抗剂 Pending CN1649845A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37609302P 2002-04-26 2002-04-26
US60/376,093 2002-04-26

Publications (1)

Publication Number Publication Date
CN1649845A true CN1649845A (zh) 2005-08-03

Family

ID=29270760

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038094436A Pending CN1649845A (zh) 2002-04-26 2003-04-24 蝇蕈碱拮抗剂

Country Status (11)

Country Link
US (1) US6890936B2 (OSRAM)
EP (1) EP1499596B1 (OSRAM)
JP (2) JP4527408B2 (OSRAM)
CN (1) CN1649845A (OSRAM)
AT (1) ATE413388T1 (OSRAM)
AU (1) AU2003228674A1 (OSRAM)
CA (1) CA2484217A1 (OSRAM)
DE (1) DE60324544D1 (OSRAM)
ES (1) ES2315494T3 (OSRAM)
MX (1) MXPA04010552A (OSRAM)
WO (1) WO2003091220A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108597A (zh) * 2014-10-31 2017-08-29 英立维尔英国有限公司 多巴胺d3受体拮抗剂化合物
CN113329748A (zh) * 2018-10-10 2021-08-31 福马治疗股份有限公司 抑制脂肪酸合酶(fasn)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200701782A3 (ru) 2003-04-24 2008-04-28 Инсайт Корпорейшн Производные азаспироалканов в качестве ингибиторов металлопротеаз
AU2005287037A1 (en) * 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US20110281853A1 (en) 2010-05-12 2011-11-17 Rishi Arora Compositions and methods for treating or preventing atrial fibrillation
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2019014427A1 (en) * 2017-07-12 2019-01-17 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04225953A (ja) * 1990-05-07 1992-08-14 Shionogi & Co Ltd スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
AU2206699A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108597A (zh) * 2014-10-31 2017-08-29 英立维尔英国有限公司 多巴胺d3受体拮抗剂化合物
CN107108597B (zh) * 2014-10-31 2020-04-17 英立维尔英国有限公司 多巴胺d3受体拮抗剂化合物
CN113329748A (zh) * 2018-10-10 2021-08-31 福马治疗股份有限公司 抑制脂肪酸合酶(fasn)

Also Published As

Publication number Publication date
JP4527408B2 (ja) 2010-08-18
JP2006507220A (ja) 2006-03-02
ES2315494T3 (es) 2009-04-01
DE60324544D1 (de) 2008-12-18
ATE413388T1 (de) 2008-11-15
MXPA04010552A (es) 2005-01-25
US20040067972A1 (en) 2004-04-08
JP2010059213A (ja) 2010-03-18
CA2484217A1 (en) 2003-11-06
US6890936B2 (en) 2005-05-10
WO2003091220A1 (en) 2003-11-06
HK1068136A1 (en) 2005-04-22
EP1499596B1 (en) 2008-11-05
AU2003228674A1 (en) 2003-11-10
EP1499596A1 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
CN1649845A (zh) 蝇蕈碱拮抗剂
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1185228C (zh) 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物
CN1301972C (zh) 作为毒覃碱拮抗剂的哌啶化合物
CN1146559C (zh) 毒蕈碱性拮抗剂
CN1589269A (zh) 杂1,2－二氢化茚:一类新型有效的大麻配体
CN1662497A (zh) N－[苯基(哌啶－2－基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用
CN1990471A (zh) Mch拮抗剂及其在治疗肥胖症方面的用途
CN1426411A (zh) 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
CN1826116A (zh) 作为黑皮素－4受体激动剂的哌啶衍生物
CN1286684A (zh) 治疗血栓形成疾病的吡咯烷、哌啶和六氢吖庚因的甲酰胺衍生物
CN1913895A (zh) 新颖的m3毒蕈碱性乙酰胆碱受体拮抗剂
CN1756740A (zh) 具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1301265A (zh) 新的用作金属蛋白酶抑制剂的取代的芳基异羟肟酸
CN1738800A (zh) 用于治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂
CN1105360A (zh) 1-[2h-1-苯并吡喃-2-酮-8-基]-哌嗪衍生物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
CN1434819A (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1121390C (zh) 用于良性前列腺增生治疗的新的取代吡啶基芳基哌嗪化合物
CN1777596A (zh) 作为选择性mch受体拮抗剂用于治疗肥胖及相关病症的联芳基四氢异喹啉哌啶
CN1461304A (zh) 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物
CN1210261C (zh) 具有5ht1a受体活性的芳基哌啶和芳基－1,2,5,6－四氢吡啶酰胺衍生物
CN1688307A (zh) 4－氨基哌啶衍生物,它们的制备方法和它们作为药物的用途
CN1812985A (zh) 治疗肥胖症的mch拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication